Sign In
Buy RHHBY
$49.06
-0.130 (-0.264%)
At Close: Jun 03, 2026
Genentech Provides Update on Astegolimab in Chronic Obstructive Pulmonary Disease
01:05am, Monday, 21'st Jul 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today topline results from the pivotal Phase IIb ALIENTO (n=1,301) and the
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on astegolimab in chronic obstructive pulmonary disease
01:00am, Monday, 21'st Jul 2025
Basel, 21 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today topline results from the pivotal phase IIb ALIENTO (n=1,301) and the phase III ARNASA (n=1,375) trials investigating astegolima
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Re
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer
07:30am, Tuesday, 15'th Jul 2025
SAN CARLOS, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclona
Smart Money Going in Senior Health: Key Stocks in Elderly Care
10:50am, Friday, 11'th Jul 2025
RHHBY, NVO, EW and SYK are ramping up senior care innovation as aging populations reshape global healthcare demand.
Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
10:41am, Tuesday, 08'th Jul 2025
Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.
Changes to the Roche Enlarged Corporate Executive Committee
01:00am, Monday, 30'th Jun 2025
Basel, 30 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Johannes (Hans) Clevers (1957), M.D., Ph.D., Head of Roche Pharma Research and Early Development (pRED) and member of the
Roche Holding AG (RHHBY) Virtual Hematology Investor Conference Transcript
05:06pm, Monday, 23'rd Jun 2025
Roche Holding AG (OTCQX:RHHBY) Virtual Hematology Investor Conference Call June 23, 2025 1:00 PM ET Company Participants Bruno Eschli - Head of Investor Relations Charles S. Fuchs - Global Head of Onc
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO [NCT05171647] study showing Lunsumio
Basel, 20 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today results from the phase III SUNMO [NCT05171647] study showing Lunsumio® (mosunetuzumab) administered subcutaneously in combinat
Roche: Despite Venclexta Study Failure, PD Program Is Another Growth Avenue
05:05pm, Monday, 16'th Jun 2025
Genentech and AbbVie noted that Venclexta failed to help treat patients with newly diagnosed higher-risk MDS; However, this drug has already been approved for several other hematological indications.
Genentech Provides Update on Phase III Verona Study
11:30am, Monday, 16'th Jun 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and AbbVie announced today the outcome from the Phase III VERONA study (NCT04401748)
RHHBY to Advance Parkinson's Disease Drug to Late-Stage Development
10:50am, Monday, 16'th Jun 2025
Roche is set to advance prasinezumab into phase III for early Parkinson's, eyeing potential first-in-class disease-modifying therapy.
Roche Pauses Commercial and Clinical Use of Elevidys After Fatal Liver Failures
02:35am, Monday, 16'th Jun 2025
The commercial and clinical use of Elevidys was discontinued after two fatal cases of acute liver failure.
Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson's Disease
01:15am, Monday, 16'th Jun 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today its decision to proceed with Phase III development of prasinezumab, a
